You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer

Article metrics

Article menu

Download PDFPDF

Poster
IGCS20_1150
164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 202023012
Dec 202037011
Jan 20214206
Feb 20211402
Mar 20213407
Apr 202118012
May 2021101
Jun 2021601
Jul 2021306
Aug 2021405
Sep 2021208
Oct 202128026
Nov 202139017
Dec 202130010
Jan 202265014
Feb 20228907
Mar 20226309
Apr 202256014
May 202234010
Jun 20224207
Jul 202259012
Aug 20223104
Sep 202267011
Oct 20222205
Nov 20223802
Dec 20222202
Jan 20231603
Feb 20234003
Mar 20233305
Apr 202346012
May 202356018
Jun 20233309
Jul 20235309
Aug 202386010
Sep 20235309
Oct 202364022
Nov 20234505
Dec 20238607
Jan 20248203
Feb 20245204
Mar 202464019
Apr 20243409
Total17120368